Mabpharm Limited (HKG:2181)
Hong Kong · Delayed Price · Currency is HKD 0.3950
0.00 (0.00%)
Jul 10, 2026, 10:42 AM HKT
Mabpharm Market Cap
Mabpharm has a market cap or net worth of 1.63 billion as of July 9, 2026. Its market cap has decreased by -20.20% in one year.
Market Cap
1.63B
Enterprise Value
1.87B
Revenue
718.98M
Ranking
n/a
PE Ratio
35.50
Stock Price
0.40
Market Cap Chart
Since May 31, 2019, Mabpharm's market cap has decreased from 4.99B to 1.63B, a decrease of -67.36%. That is a compound annual growth rate of -14.56%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 10, 2026 | 1.63B | -21.00% |
| Dec 31, 2025 | 2.06B | 78.57% |
| Dec 31, 2024 | 1.15B | -39.13% |
| Dec 29, 2023 | 1.90B | 5.75% |
| Dec 30, 2022 | 1.79B | -56.50% |
| Dec 31, 2021 | 4.12B | -4.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Frontage Holdings | 2.17B |
| PegBio | 2.16B |
| AIM Vaccine | 2.06B |
| Clover Biopharmaceuticals | 2.01B |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 1.59B |
| SinoMab BioScience | 1.58B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.55B |
| HighTide Therapeutics | 1.50B |